Obio Technology (Shanghai) Corp., Ltd. (SHA:688238)
7.41
-0.02 (-0.27%)
At close: Nov 6, 2025
SHA:688238 Revenue
Obio Technology (Shanghai) Corp. had revenue of 60.50M CNY in the quarter ending September 30, 2025, a decrease of -14.56%. This brings the company's revenue in the last twelve months to 244.64M, down -2.80% year-over-year. In the year 2024, Obio Technology (Shanghai) Corp. had annual revenue of 248.15M with 21.16% growth.
Revenue (ttm)
244.64M
Revenue Growth
-2.80%
P/S Ratio
19.07
Revenue / Employee
353.52K
Employees
692
Market Cap
4.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 248.15M | 43.34M | 21.16% |
| Dec 31, 2023 | 204.81M | -86.50M | -29.69% |
| Dec 31, 2022 | 291.30M | 36.36M | 14.26% |
| Dec 31, 2021 | 254.95M | 112.18M | 78.57% |
| Dec 31, 2020 | 142.77M | 79.85M | 126.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 43.09B |
| WuXi AppTec | 43.07B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Medicine | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |